ACM

Aisling Capital Management Portfolio holdings

AUM $360M
This Quarter Return
+48.42%
1 Year Return
+114.67%
3 Year Return
+1,171.46%
5 Year Return
+892.24%
10 Year Return
–
AUM
$261M
AUM Growth
+$261M
Cap. Flow
+$1.05M
Cap. Flow %
0.4%
Top 10 Hldgs %
97.6%
Holding
13
New
–
Increased
1
Reduced
–
Closed
–

Top Buys

1
ZSAN
Zosano Pharma Corporation
ZSAN
$1.05M

Top Sells

No sells this quarter

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Shares
Change % 		Capital Flow
BBIO icon
1
BridgeBio Pharma
BBIO
$9.89B
$134M 51.51% 3,835,722 – –
EIDX
2
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$64.5M 24.71% 1,123,630 – –
TECX
3
Tectonic Therapeutic, Inc. Common Stock
TECX
$478M
$18M 6.89% 893,079 – –
SYRE icon
4
Spyre Therapeutics
SYRE
$996M
$9.86M 3.78% 1,291,151 – –
BCEL
5
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$6M 2.3% 387,653 – –
MRKR icon
6
Marker Therapeutics
MRKR
$12M
$5.76M 2.21% 2,000,000 – –
OBSV
7
DELISTED
ObsEva SA Ordinary Shares
OBSV
$5.3M 2.03% 1,386,338 – –
ZSAN
8
DELISTED
Zosano Pharma Corporation
ZSAN
$4.13M 1.58% 2,718,226 +689,655 +34% +$1.05M
VIRX
9
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$3.41M 1.31% 10,100,000 – –
RCUS icon
10
Arcus Biosciences
RCUS
$1.13B
$3.37M 1.29% 333,333 – –
VRNA
11
Verona Pharma
VRNA
$9.16B
$2.55M 0.98% 443,596 – –
NBRV
12
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$2.52M 0.97% 1,910,287 – –
ACRS icon
13
Aclaris Therapeutics
ACRS
$209M
$1.2M 0.46% 634,455 – –